GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Scaled Net Operating Assets

Sumitomo Pharma Co (Sumitomo Pharma Co) Scaled Net Operating Assets : 0.64 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sumitomo Pharma Co's operating assets for the quarter that ended in Dec. 2023 was $7,065 Mil. Sumitomo Pharma Co's operating liabilities for the quarter that ended in Dec. 2023 was $2,115 Mil. Sumitomo Pharma Co's Total Assets for the quarter that ended in Sep. 2023 was $7,771 Mil. Therefore, Sumitomo Pharma Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.64.


Sumitomo Pharma Co Scaled Net Operating Assets Historical Data

The historical data trend for Sumitomo Pharma Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Scaled Net Operating Assets Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.99 0.55 0.49 0.39

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.43 0.57 0.61 0.64

Competitive Comparison of Sumitomo Pharma Co's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Scaled Net Operating Assets falls into.



Sumitomo Pharma Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sumitomo Pharma Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2023 )
=(Operating Assets (A: Mar. 2023 )-Operating Liabilities (A: Mar. 2023 ))/Total Assets (A: Mar. 2022 )
=(7265.141-2942.027)/11030.829
=0.39

where

Operating Assets(A: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=8489.492 - 1224.351
=7265.141

Operating Liabilities(A: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=5446.181 - 1826.426 - 677.728
=2942.027

Sumitomo Pharma Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(7064.547-2115.098)/7770.672
=0.64

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=7361.849 - 297.302
=7064.547

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4975.479 - 1279.706 - 1580.675
=2115.098

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sumitomo Pharma Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.